Radiopharm Theranostics Limited (RADX) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

Per the Roarable RQD rating, RADX scores 46 out of 100, a D grade labeled "Roarable Sell — Underperform / Distribution Warning." The five pillars are: Fundamental Cash Engine at 12 of 20 (ROIC 0%; FCF yield 0%), Whale 13F Flow at 3 of 20 (institutional accumulation and options positioning), Insider Conviction at 9 of 20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 9 of 20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 13 of 20 (Altman Z 2.5; Piotroski F 6/9; Debt/Equity 0.5). The weakest pillar is institutional flow, which is the most direct signal of professional conviction, and the cash-engine pillar reflects zero reported return on invested capital and zero free-cash-flow yield. The forensic balance sheet is the strongest pillar, which suggests balance-sheet solvency is comparatively better supported than cash generation. For a prospective investor, the rating frames the stock as one where the source data offers limited evidence of cash generation or institutional accumulation, so any upside case depends on factors outside the scored pillars. The rating is an analytical framework, not a recommendation.

Per the recent news feed, the most substantive catalyst is the report that Radiopharm completed a productive end-of-Phase 2 meeting with the U.S. Food and Drug Administration for its pivotal RAD101 program, reported across several outlets. A second headline reports that after A$10.7M in quarterly operating cash use, the company received $8M in secured funding, which bears directly on runway. A third headline references an anticipated tax incentive supporting clinical trial funding. A price-action headline reports shares slipping to $1.00 as they tested lower support. The feed carries no proprietary signals, and the Butterfly graph reports no supply-chain links. Risk watch items include the funding dependence implied by the cash-use and secured-funding headlines, and the price pressure reported at the lower support level. The news feed is labeled as market wire, and its headlines are not verified against company filings in the source data.

• What are the company's reported revenue, operating income, net income, and free cash flow across recent periods, given the financial statements are absent from the source data?
• What are the terms, dilution effects, and remaining runway associated with the $8M in secured funding?
• What is the stage, timeline, and cost of the pivotal RAD101 program following the end-of-Phase 2 meeting?
• Who are the company's partners, suppliers, and any commercial counterparties, and how concentrated is the program dependency?
• What institutional or insider holdings exist, since the holders and analyst sections are empty in the source data?